CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- Targanta Therapeutics Corporation today announced that 23 presentations will showcase its lead antibiotic candidate, oritavancin, and its antibiotic drug discovery platform at the upcoming 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Chicago, September 17-20, 2007.
Thomas Parr, Ph.D., Chief Scientific Officer of Targanta Therapeutics commented on the meeting: “We are very proud of the body of data being presented on behalf of Targanta at ICAAC this year-a true testament, we believe, to the efforts and expertise of our scientists and collaborators. We continue to be encouraged by the breadth of data supporting the differentiating characteristics of oritavancin and are pleased to be able to present for the first time promising data on our pre-clinical osteomyelitis program.”
Throughout the meeting, multiple posters will highlight the in vitro activity of oritavancin, Targanta’s investigational antibiotic for the treatment of gram-positive infections, against a wide spectrum of antibiotic susceptible and resistant gram-positive bacteria. In addition, two presentations at ICAAC will highlight Targanta’s proprietary drug discovery platform, which utilizes bisphosphonate prodrugs of antibiotics to generate molecules that deliver antibiotics directly to the bone.
The following abstracts have been accepted for poster or slide presentation at ICAAC:
Date Time Number Type Author Title Monday, 12:00- A-49 Poster Lehoux PK-PD of Oritavancin Sept. 17 1:00PM CDT (ORI) Against Streptococcus pneumoniae (SP) in a Murine-Pneumonia Infection Model A-50 Poster McKay In vitro Post Antibiotic Effect Studies of Oritavancin against Staphylococcus aureus and Enterococci A-51 Poster Bhavnani Use of Pharmacokinetic- Pharmacodynamic (PK-PD) Principles to Guide Clinical Drug Development for Oritavancin (ORI) D-241 Poster Tomfohrde Newly Defined In Vitro Quality Control Ranges for Oritavancin Broth Microdilution Testing and the Effect of Variations in Testing Conditions on MIC Results D-242 Poster Arhin Activity of Oritavancin against Drug-resistant Staphylococcus aureus in the Presence of Polysorbate-80 Wed., 10:00AM- B-1356 Slide Lehoux In Vivo Efficacy of a New Sept. 19 10:15AM Osteotropic Prodrug in a CDT Rabbit Model of Chronic Osteomyelitis 10:15AM- B-1357 Slide Tanaka Preparation and In vitro 10:30AM Evaluation of CDT Fluoroquinolone Prodrugs for the Prevention and Treatment of Osteomyelitis Wed., 11:15AM- A-1437 Poster Van Bambeke Comparative Intracellular Sept. 19 12:15PM Activity of 10 CDT Antistaphylococcal Antibiotics (AABs) Against a Stable Small Colony Variant (SCV) of S. aureus in a model of human THP-1 macrophages C1-1471 Poster Arhin Mechanisms of Action of Oritavancin in Staphylococcus aureus C1-1472 Poster Belley Differential Targeting of Cell Wall Assembly Systems by Oritavancin C1-1473 Poster Rafai Far Cell-Wall Binding Sites of Desleucyl (fluorophenyl) benzylchloroeremomycin, a Damaged Oritavancin Analogue, in Staphylococcus aureus C1-1474 Poster Wang Probing the Mechanism of Inhibition of Bacterial Peptidoglycan Glycosyltransferases by Glycopeptide Analogs Wed., 12:15PM- E-1612 Poster Moeck In Vitro Activity Profile Sept. 19 1:15PM of Oritavancin against a CDT Broad Spectrum of Aerobic and Anaerobic Bacterial Pathogens E-1613 Poster Grover In Vitro Activity Profile of Oritavancin (ORI) against Organisms Demonstrating Key Resistance Profiles to Other Antimicrobial Agents E-1614 Poster McKay In Vitro Time Kill Studies of Oritavancin against Drug-resistant Isolates of Staphylococcus aureus and Enterococci E-1615 Poster Sahm Anti-Enterococcal Activity Profile or Oritavancin, a Potent Lipoglycopeptide under Development for Use against Gram-Positive Infections E-1616 Poster Draghi Anti-Streptococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use against Gram-Positive Infections E-1617 Poster Sahm In Vitro Activity Profile of Oritavancin against Resistant Staphylococcal Populations from a Recent Surveillance Initiative E-1618 Poster Wilcox In Vitro Susceptibility of Genotypically Distinct Clostridium difficile Strains to Oritavancin E-1619 Poster Belley Synergistic Effects of Oritavancin Tested in Combination with Other Agents E-1620 Poster Belley Pharmacokinetic Concentrations of Oritavancin Kill Stationary-Phase and Biofilm Staphylococcus aureus in Vitro E-1621 Poster Arhin Impact of Human Serum Albumin on Oritavancin In vitro Activity against Staphylococcus aureus E-1627a Poster Baines Activity of Metronidazole, Vancomycin and Oritavancin against Epidemic Clostridium difficile spores
About Oritavancin
Oritavancin is a novel semi-synthetic lipoglycopeptide antibiotic candidate with potent bactericidal (killing) activity against a broad spectrum of gram-positive bacteria. The product candidate has been tested in over 1500 patients and has completed two Phase 3 studies for the treatment of complicated skin and skin structure infection (cSSSI) in which the primary endpoints were met. Targanta believes oritavancin’s properties may give it distinct advantages over currently marketed therapies and expects to submit a New Drug Application to the U.S. Food and Drug Administration in the first quarter of 2008 seeking to commercialize oritavancin for the treatment of cSSSI.
About Targanta Therapeutics
Targanta Therapeutics Corporation is a privately held biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company’s pipeline includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic, for which Targanta intends to seek U.S. regulatory approval in early 2008, as well as a number of antibacterial agents in pre-clinical development. The company has operations in Cambridge, MA, Indianapolis, IN, Montreal, Quebec, Canada and Toronto, Ontario, Canada. For further information about Targanta, visit the company’s website at www.targanta.com.
Disclaimer
All forward-looking statements and other information included in this press release are based on information available to Targanta as of the date hereof, and Targanta assumes no obligation to update any such forward-looking statements or information. Targanta’s actual results could differ materially from those described in Targanta’s forward-looking statements.
Targanta Therapeutics Corporation
CONTACT: Investors, Mark Leuchtenberger, President & Chief ExecutiveOfficer of Targanta Therapeutics Corporation, +1-617-577-9020 x222; orfinancial media, Brian Ritchie of Financial Dynamics, +1-212-850-5683, forTarganta Therapeutics; or scientific media Annie Moore of Spectrum ScienceCommunications, +1-202-955-6222 x2547, for Targanta Therapeutics
Web site: http://www.targanta.com/
